Skip to content
value.today
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2018

Formerly T-Scan Therapeutics, Inc.

Total raised
$123 M
2 rounds on record
Latest round
$100 M
Jan 2021
First round on record
Jul 2019
Today
Went public
See the company page

TScan Therapeutics, Inc. is listed today as TScan Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of TScan Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2021$100 MNo. 2$50 to $250 million

TScan Therapeutics, Inc.: Raise no. 2, Jan 2021

Investors in this round

16 investors had bought by the notice of Jan 28, 2021: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for TScan Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$100 M of $100 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Southwell · Executive Officer, Director
  • Andrew Hedin · Director
  • Brian Silver · Director
  • Christoph Westphal · Director
  • Doug Fambrough · Director
  • Ittai Harel · Director
  • Nandita Shangari · Director
  • Timothy Barberich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Southwell, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 28, 2021. Read the notice at the SEC.

equitySEC
Jul 2019$23 MNo. 1$10 to $50 million

TScan Therapeutics, Inc.: Raise no. 1, Jul 2019

Investors in this round

9 investors had bought by the notice of Jul 26, 2019: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for TScan Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$23 M of $23 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Southwell · Executive Officer, Director
  • Robert Crane · Executive Officer
  • Campbell Murray · Director
  • Christoph Westphal · Director
  • Hannes Smarason · Director
  • Lea Hachigian · Director
  • Steve Kraus · Director
  • Timothy Barberich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Southwell, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 26, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company TScan Therapeutics, Inc., its revenue in fiscal 2025 came from these business segments: Reportable $10.32 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • TScan Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2021).

    SEC Form D · Jan 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2021

Products and services#

No products or services of TScan Therapeutics, Inc. are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in TScan Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
667, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Baker Bros. Advisors (GP) LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Baker Bros. Advisors LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Baker Brothers Life Sciences LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Timothy J. BarberichPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 16 investors.

Largest shareholders today

Institutions holding TScan Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by TScan Therapeutics, Inc.
NameRoleNamed in
David SouthwellExecutive officerJan 2021
Robert CraneExecutive officerJul 2019
Andrew HedinDirectorJan 2021
Brian SilverDirectorJan 2021
Christoph WestphalDirectorJan 2021
David SouthwellDirectorJan 2021
Doug FambroughDirectorJan 2021
Ittai HarelDirectorJan 2021
Nandita ShangariDirectorJan 2021
Timothy BarberichDirectorJan 2021
Campbell MurrayDirectorJul 2019
Hannes SmarasonDirectorJul 2019
Lea HachigianDirectorJul 2019
Steve KrausDirectorJul 2019

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.